Literature DB >> 9039336

Bone mineral density in relation to glucocorticoid substitution therapy in adult patients with 21-hydroxylase deficiency.

J Jääskeläinen1, R Voutilainen.   

Abstract

OBJECTIVE: There are only limited data on bone mineral density (BMD) in adult patients with 21-hydroxylase deficiency (21-OHD). We have defined the effects of different glucocorticoid substitution therapies on BMD and body composition in these patients.
DESIGN: Cross-sectional. PATIENTS: Thirty-two adult patients with 21-OHD. MEASUREMENTS: Patients were examined auxologically and biochemically. BMD was examined in the left femoral neck and lumbar vertebrae 2-4 (L2-4) with dual X-ray absorptiometry. The results were compared with national reference data.
RESULTS: Mean height was 170.1 cm (-1.36 standard deviation scores (SDS) for the men and 156.3 cm (-1.68 SDS) for the women. These were significantly less (P < 0.001) than the mean national final heights. Mean BMD Z-score ((raw score - population reference mean)/SD) was -0.52 in L2-4 and -0.83 in the left femoral neck. Both these values were significantly less than the reference mean values (P = 0.045 and < 0.001, respectively). Both current and long-term mean glucocorticoid doses showed significant negative correlations with BMD in the left femoral neck as well as in L2-4. Patients substituted with hydrocortisone were less often over-treated and had better BMD Z-score means than patients substituted with prednisone, prednisolone or dexamethasone.
CONCLUSIONS: In the follow-up of patients with 21-hydroxylase deficiency, care needs to be exercised to keep the glucocorticoid substitution dose to a minimum. In most cases decreased bone mineral density is a result of over-substitution.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9039336     DOI: 10.1046/j.1365-2265.1996.8620871.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  20 in total

Review 1.  Clinical perspectives in congenital adrenal hyperplasia due to 11β-hydroxylase deficiency.

Authors:  Krupali Bulsari; Henrik Falhammar
Journal:  Endocrine       Date:  2016-12-07       Impact factor: 3.633

2.  Cortical bone mineral density in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  Diala El-Maouche; Suzanne Collier; Mala Prasad; James C Reynolds; Deborah P Merke
Journal:  Clin Endocrinol (Oxf)       Date:  2014-06-28       Impact factor: 3.478

Review 3.  Clinical outcomes in the management of congenital adrenal hyperplasia.

Authors:  Henrik Falhammar; Marja Thorén
Journal:  Endocrine       Date:  2012-01-07       Impact factor: 3.633

4.  Pituitary gonadal axis and child rate in males with classical 21-hydroxylase deficiency.

Authors:  J Jääskeläinen; O Kiekara; M Hippeläinen; R Voutilainen
Journal:  J Endocrinol Invest       Date:  2000-01       Impact factor: 4.256

5.  Alternative strategies for the treatment of classical congenital adrenal hyperplasia: pitfalls and promises.

Authors:  Karen J Loechner; James T McLaughlin; Ali S Calikoglu
Journal:  Int J Pediatr Endocrinol       Date:  2010-06-24

6.  Bone health should be an important concern in the care of patients affected by 21 hydroxylase deficiency.

Authors:  Anne Bachelot; Zeina Chakhtoura; Dinane Samara-Boustani; Jérome Dulon; Philippe Touraine; Michel Polak
Journal:  Int J Pediatr Endocrinol       Date:  2010-09-28

Review 7.  [Testicular adrenal rest tumors (TART) in adult men with classic congenital adrenal hyperplasia (CAH)].

Authors:  P Knape; N Reisch; H-G Dörr; M Reincke; S Lenk; M Quinkler
Journal:  Urologe A       Date:  2008-12       Impact factor: 0.639

8.  Bone mineral status in children with congenital adrenal hyperplasia.

Authors:  Amy Fleischman; Julie Ringelheim; Henry A Feldman; Catherine M Gordon
Journal:  J Pediatr Endocrinol Metab       Date:  2007-02       Impact factor: 1.634

Review 9.  Management of adolescents with congenital adrenal hyperplasia.

Authors:  Deborah P Merke; Dix P Poppas
Journal:  Lancet Diabetes Endocrinol       Date:  2013-11-15       Impact factor: 32.069

10.  Approach to the adult with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  Deborah P Merke
Journal:  J Clin Endocrinol Metab       Date:  2008-03       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.